Arjun Srinivasan
Datos Biográficos
| ID | 6080106 |
|---|---|
| NOMBRE | Arjun Srinivasan |
| NOMBRES | Arjun |
| APELLIDO | Srinivasan |
| FIRMA | SRINIVASAN A |
| AFILIACIONES | Katherine Ellingson, Kelly McCormick, Ronda Sinkowitz-Cochran, Tiffanee Woodard, John Jernigan, and Arjun Srinivasan are with the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta GA. Kimberly Rask is with the Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta. |
| ORCID | 0000-0002-9529-5344 |
| VERIFICADO | Sí |
| TOTAL DE OBRAS | 3 |
| TOTAL DE CITAS | 1 |
| TOTAL COMO AUTOR | 3 |
| TOTAL COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2012 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2025 |
| ÍNDICE H | 1 |
Benefit-Risk Reporting for FDA-Cleared Artificial Intelligence−Enabled Medical Devices
This cross-sectional study suggests that despite increasing clearance of AI/ML devices, standardized efficacy, safety, and risk assessment by the FDA are lacking. Dedicated regulatory pathways and postmarket surveillance of AI/ML safety events may address these challenges
Enhancement of Health Department Capacity for Health Care–Associated Infection Prevention Through Recovery Act–Funded Programs
Objectives. We evaluated capacity built and outcomes achieved from September 1, 2009, to December 31, 2011, by 51 health departments (HDs) funded through the American Recovery and Reinvestment Act (ARRA) for health care–associated infection (HAI) program development. Methods. We defined capacity for HAI prevention at HDs by 25 indicators of activity in 6 categories: staffing, partnerships, training, technical assistance, surveillance, and prevent…
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria
Enhancement of Health Department Capacity for Health Care–Associated Infection Prevention Through Recovery Act–Funded Programs
Objectives. We evaluated capacity built and outcomes achieved from September 1, 2009, to December 31, 2011, by 51 health departments (HDs) funded through the American Recovery and Reinvestment Act (ARRA) for health care–associated infection (HAI) program development. Methods. We defined capacity for HAI prevention at HDs by 25 indicators of activity in 6 categories: staffing, partnerships, training, technical assistance, surveillance, and prevent…
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria
Enhancement of Health Department Capacity for Health Care–Associated Infection Prevention Through Recovery Act–Funded Programs
Objectives. We evaluated capacity built and outcomes achieved from September 1, 2009, to December 31, 2011, by 51 health departments (HDs) funded through the American Recovery and Reinvestment Act (ARRA) for health care–associated infection (HAI) program development. Methods. We defined capacity for HAI prevention at HDs by 25 indicators of activity in 6 categories: staffing, partnerships, training, technical assistance, surveillance, and prevent…
Benefit-Risk Reporting for FDA-Cleared Artificial Intelligence−Enabled Medical Devices
This cross-sectional study suggests that despite increasing clearance of AI/ML devices, standardized efficacy, safety, and risk assessment by the FDA are lacking. Dedicated regulatory pathways and postmarket surveillance of AI/ML safety events may address these challenges
Medicine (2 obras) · Political science (2 obras) · Antibiotic Resistance in Bacteria (1 obras) · Antibiotic Use and Resistance (1 obras) · Antimicrobial Resistance in Staphylococcus (1 obras) · Artificial Intelligence in Healthcare and Education (1 obras) · Biology (1 obras) · Conformity assessment (1 obras) · Drug resistance (1 obras) · Environmental health (1 obras)